Objective: Left ventricle (LV) function was shown to be a principal determinant of morbidity and mortality in both uncorrected and surgically corrected mitral regurgitation (MR). However, the cellular mechanisms that develop in the LV remodeling secondary to volume overload in chronic severe MR is still not well defined. In single ventricular myocyte, a reduced contraction and slowed relaxation have been mainly attributed to defective intracellular Ca 2+ currents. Between several Ca 2+ handling proteins, sarcoplasmic reticulum Ca
Introduction
The surgical correction in mitral regurgitation (MR) performed at optimal time restores the proper cardiac function along with the improvement in functional status and survival. That is why, recently, early surgery is increasingly recommended for patients with degenerative MR in order to prevent irreversible decline in left ventricle (LV) function.
The onset of symptoms of heart failure (HF) and LV dysfunction predicts a poor prognosis after surgery. Moreover, in the patients with already diagnosed severe MR, the progression of LV muscle dysfunction is quite variable.
Although both experimental and human studies suggest that LV failure due to chronic severe MR is caused, at least in part, to inherent defects in LV contractile function, the specific changes in myocardial composition and gene expression are largely unknown [1, 2] .
There is accumulating body of evidence that both contractility and relaxation are mainly dependent upon the rise and fall of cytosolic Ca 2+ , closely linked to altered expression/function of the Ca 2+ -regulatory proteins [3] [4] [5] . Among several Ca 2+ handling proteins, sarcoplasmic reticulum Ca 2+ -ATPase 2 (SERCA2) decreased expression/function has been claimed to be a molecular early sign of decompensation, however, not confirmed by all authors. Diastolic calcium removal from the cytosol occurs by SERCA2 which transports Ca 2+ from cytosol into the sarcoplasmic reticulum (SR) and also exchange of Ca 2+ for Na + outside the sarcolemma by the Na + /Ca 2+ exchanger (NCX). The amount of Ca 2+ released by the SR depends on its Ca 2+ load and also Ca 2+ gradient between the SR and cytosol, so there is a general agreement that SERCA2 determines not only the extent and rate of relaxation but also the rate and amplitude of contraction [6] . However, the role of SERCA2 expression changes in LV ventricular remodeling secondary to chronic MR is not yet established.
SERCA2 is encoded by three different genes (SERCA1, SERCA2, and SERCA3) and six distinct isoforms are expressed. In cardiac muscle cells, the SERCA2 gene encodes two alternatively spliced Ca 2+ -ATPase mRNA isoforms: SERCA2a and 2b [7] . Although there is an important functional difference between both SERCA2 isoforms, indeed, to our knowledge, none of studies indicated a reduced mRNA level of SERCA2 in failing heart and discriminated between both isoforms.
Accordingly, the purpose of this investigation was to determine whether and which extend myocardial SERCA2 gene on mRNA and protein expression occur in LV remodeling due to chronic severe MR. Also to determine whether a relationship exists between SERCA2 expression and parameters of LV volume overload and remodeling.
Materials and methods
The investigation conforms with principles outlined in the Declaration of Helsinki. The informed consent was obtained from all patients participating in the study according to the protocol approved by the Local Ethics Committee.
The study group was composed of 12 consecutive patients who presented overt HF secondary to pure, severe, chronic nonischemic MR, excluded from mitral valve repair, during cardiac surgery due to technical reasons. Patients with primary cardiomyopathy and secondary MR, coronary artery disease, other significant valve disease apart from tricuspid regurgitation were excluded from the study group.
Patients evaluation
Each patient underwent right heart catheterization; pulmonary artery pressures (PAP) and pulmonary wedge pressures (PWP) were measured. Cardiac output was determined by the thermodilution method; cardiac index (CI) and stroke volume index (SVI) were calculated. Two-dimensional (2D), M-mode and color Doppler transthoracic echocardiography on left lateral position on commercially available equipment (VingmedV) using standard views. 2D parasternal long/short axis and apical views were performed for mitral anterior/posterior leaflets assessment. The LV end-diastolic/end-systolic diameters (EDD/ESD) and end-diastolic/end-systolic volumes (EDV/ ESV), together with ejection fraction (EF) and left atrium size (LA) were measured/calculated according to the recommendations of the American Society of Echocardiography. Color Doppler was used for assessment of the presence and severity of MR. MR severity was measured by a semiquantitative method-graded as severe MR if the percent ratio of the maximal flow disturbance produced by the MR jet to left atrial area was >40%.
Before surgery, the blood samples were obtained for the hormonal evaluation: plasma noradrenaline level (NA), plasma renin activity (PRA), angiotensin II (ANGII), aldosterone (ALD). Neurohumoral assays were performed using commercially available kits: PRA/ALD by radioimmunoassay (DiaSorin s.r.l., Italy), ANGII by RIA (Buhlmann Laboratories AG, Switzerland), after previous reverse-phase extraction of the plasma samples with phenylsilysilca columns, NA by HPLC method (BioRad, USA).
Preparation of cardiac tissue
During mitral valve replacement (with posterior leaflet and both chordals preservation), samples of LV anterior papillary muscle weighing 100-150 mg were obtained, avoiding connective tissue, endocardium, and vessels. The biopsies were rinsed immediately, blotted dry, frozen in liquid nitrogen, and kept at À80 8C until use.
Non-failing hearts (NFH), from four adults aged 22-58 years, without previous medical history or any abnormalities in ECG and echocardiography (LV dimensions/contractility within normal ranges) who died from head trauma and received dopamine (2-5 mg/(kg min)) before death were used as controls. They were rejected for transplantation for other reasons than depressed cardiac function. The samples were obtained from LV papillary muscle.
RNA isolation and RT-PCR analysis
Total cellular RNA was isolated from samples using Chomczynski and Sacchi's modified procedure [8] . Total RNA concentrations were assessed spectrophotometrically, RNA yield were similar in NFH and MR group (0.52 AE 0.04 mg RNA/mg tissue and 0.49 AE 0.08 mg RNA/mg tissue, respectively).
Reverse transcription (RT) was performed using RNAsine (40 U), dNTP mix 25 mM (0.75 mM), Oligo (dT) (1750 ng), MgCl 2 , (2.5 mM), TPCR 4.0 ml, H20 DEPC, MMLV (400 U), and 3 mg of total RNA all in a total volume of 50 ml. Reverse transcriptase was inactivated at 99 8C for 5 min and used for cDNAs synthesis by the PCR method.
For PCR experiments, MgCl 2 (0.5 mM), TPCR 10X, sense primers (150 ng), antisense primers (150 ng) and Taq polymerase (2.5 U) were added to 10 ml of the RT reaction mixture, for a total reaction volume of 50 ml. For SERCA2a, upper primer (5 0 -sense) TTT CCT ACA GTG TAA AGA GGA CAA CC3 0 (26 mer) and lower primer (3 0 -antisense) TTC CAG GTA GTT GCG GGC CAC AAA3 0 (24 mer, predicted length of the PCR product 364 bp) were used. For SERCA2b, upper primer (5 0 -sense) TTT CCT ACA GTG TAA AGA GGA CAA CC3 0 (26 mer, same as for SERCA2a) and lower primer (3 0 -antisense) AGA CCA GAA CAT ATC GCT AAA GTT3 0 (24 mer, predicted length of the PCR product 513 bp) were used [9, 10] . For GAPDH, [11] upper primer (5 0 -sense) CTT CAT TGA CCT CAA CTA CAT GGT and lower primer (3 0 -antisense) CTC AGT GTA GCC CAG GAT GCC CTT3 0 (predicted length of the PCR product 726 bp) were used. Thirty-five PCR amplification cycles were run using a thermal cycler (Perkin-Elmer, San Diego, USA) as following: denaturation at 95 8C, 0.5 min; annealing at 58 8C, 1 min; extension at 72 8C, 1 min, and heating at 72 8C, 10 min.
Semi quantitative analysis of PCR products was estimated after electrophoresis on 1% agarose gels using ethidium bromide as a dye. Quantifications of SERCA2a/2b and GAPDH PCR products were performed by densitometric analysis after gel scanning (GelDoc 1000, Biorad) using Molecular Analyst (BioRad) software and normalized to GAPDH (Fig. 1 ).
Protein studies
The protein studies were performed on crude homogenates (CSR) according to Rannou et al. [12] . Protein concentration was determined in triplicates by the method of Lowry et al. [13] using bovine serum albumin as a standard. The yield of protein per gram of wet weight was 75 AE 9.5 mg/ g and 66.5 AE 12.5 mg/g from NFH and MR group, respectively.
Equal amounts of protein from all samples were subjected to SDS-PAGE according to Laemmli method [14] and blotted to PVDF membrane. Membranes were saturated in 5% fat-free milk, incubated for 2 h with a specific monoclonal antibody anti-SERCA2 (gift from Professor D.O. Levitsky) diluted in 1:1500 in TBS containing 0.1% Tween 20. Lack of specific antibodies did not allow differentiating between the two isoforms. The specific bands were revealed by ECL technique on Kodak X-ray films. Quantifications were performed by densitometric analysis after ECL film scanning. Signals from proteins stained with Coomassie Blue R 250 and actin were used to normalize the specific signal in each lane (Fig. 2) .
Statistical analysis
Data were expressed as means AE standard deviations. The two-sided significance level was p < 0.05. The analysis comparing study and control group was performed with ttest. In the assessment between mRNA of both SERCA2 isoforms, proteins and clinical variables Pearson's correlations were calculated.
Results

Study group population
The MR group composed of 12 patients (4 women, 8 men) with mean age 58 AE 11 years and echocardiographically documented severe, chronic nonischemic MR (myxomatous mitral valve degeneration: anterior leaflet-4 patients; posterior leaflet-6 patients; both leaflets-2 patients). No further histological analysis of the excised leaflets was performed.
All patients presented symptoms of HF and met the criteria for NYHA class III (nine patients) or IV (three patients). The mean period from the initial MR diagnosis to study inclusion was 24 years (AE2). Atrial fibrillation was present in all patients.
All patients had echocardiographic evidence of secondary LV dilatation: diastolic (EDD-70 AE 7 mm; EDV-260 AE 65 ml), systolic (ESD-46 AE 10 mm; ESV-102 AE 68 ml) with LA enlargement (66 AE 13 mm). They presented with elevated PAP/ PWP and depressed CI/SVI and also elevated NA, PRA, and ALD plasma levels (supine position) ( Table 1) .
Comparison of mRNA levels between MR patients and non-failing myocardium
The mRNA levels of SERCA2a and SERCA2b (Fig. 3a) were significantly lower in MR group than in NFH. A significant correlation between SERCA2a and 2b mRNA expressions was observed ( Table 2) . 
Comparison of protein accumulation between MR group and non-failing myocardium
Protein levels of SERCA2 were normalized to actin or total protein levels. MR group did not differ from NFH group neither in actin protein levels (1.8 AE 0.15 vs 1.9 AE 0.1, ns, arbitrary densitometric units per milligram of protein, respectively) nor after normalization actin to total protein levels (0.35 AE 0.03 vs 0.38 AE 0.04, ns, arbitrary densitometric units per milligram of protein). A significant decrease of the protein accumulation of the SERCA2 (after normalization to both actin and all protein levels) in whole MR group compared to NFH was observed. However, within the MR group the lack of homogeneity in the changes in SERCA2 protein expression was discovered. The changes in SERCA2 protein levels range from normal levels to decrease by 60% or 58% after normalization to actin protein levels or all proteins (Fig. 3b) , respectively. Moreover, a significant correlation between SERCA2a/2b mRNA and SERCA2 protein expressions was observed ( Table 2) . 3.4. Relation between clinical parameters and SERCA2 expression SERCA2a and 2b mRNA did not correlate with clinical and plasma hormonal parameters, a negative correlation between the protein levels of SERCA2 normalized to actin (r = À0.64; p = 0.053) and trend towards negative correlation between the protein levels of SERCA2 normalized to all protein levels (r = À0.67; p = 0.07) and LV diastolic diameter were observed (Table 3 ).
Discussion
LV function has been shown to be a principal determinant of morbidity and mortality in both uncorrected and surgically corrected mitral regurgitation. Even paradoxically mitral valve surgery abruptly increases afterload by elimination of the unloading effect of the regurgitant flow to the lowpressure pulmonary circuit and may precipitate development/progression of overt, left ventricle dysfunction. Moreover, also the cellular mechanisms that develop in the myocardium during transition from the compensated to the decompensated phase are largely unknown [2] .
Over the past decade, both human (on LV papillary muscle-which in fact is believed to represent the changes in LV free wall) and experimental studies of mitral regurgitation show reduced myosin content within the myocardium [15] . However, Mulieri et al. [16] did not confirm the previous finding indicating that a deficiency in cyclic adenosine monophosphate production might be the cause of reduced contractility. More recently, Oral et al. [17] reported the relationship between cytokines and level of LV remodeling in volume overload.
The present work, to our knowledge, for the first time assessed the changes on SERCA2 expression in LV dilatation due to chronic severe MR.
All of the studies on the failing human hearts on SERCA2 published by now indicated a reduced mRNA level [18] . However, in spite of the obvious functional difference between both SERCA2 isoforms indeed, none of the study discriminate the two isoforms SERCA2a and 2b. Whereas SERCA2a is expressed at high levels in cardiac muscle, the ubiquitous SERCA2b is found in almost all cell types. While SERCA2b, in comparison to SERCA2a, has nearly twofold higher affinity for calcium ion, it also presents lower maximal catalytic turnover rate than SERCA2a.
Moreover, the recent transgenic mouse experiments have shown that even the full suppression of the SERCA2a could be partially compensated by the expression of SERCA2b isoform Table 2 Relation between mRNA SERCA2a/2b levels normalized to GAPDH; and protein SERCA2 normalized to actin and total protein levels SERCA2a/GAPDH: mRNA levels of SERCA2a normalized to GAPDH; SERCA2b/GAPDH: mRNA levels of SERCA2b normalized to GAPDH; SERCA2/act: protein levels of SERCA2 normalized to actin; and SERCA2/total protein: protein levels of SERCA2 normalized to total protein levels. Table 3 Relation between clinical parameters and SERCA2 expression Echocardiographic data: EDD-end-diastolic diameter; EDV-end-diastolic volume; ESD-end systolic diameter; ESV-end systolic volume; EF-ejection fraction. Right-sided catheterization data: PWP-pulmonary wedge pressure; PAP-pulmonary artery pressure; CI-cardiac index; and SVI-stroke volume index. Hormonal data: NA-free plasma noradrenaline; PRA-plasma renin activity; ANGII-angiotensin II level; and ALD-aldosterone level. SERCA2a/ GAPDH-mRNA levels of SERCA2a normalized to GAPDH; SERCA2b/GAPDHmRNA levels of SERCA2b normalized to GAPDH; SERCA2/act-protein levels of SERCA2 normalized to actin; and SERCA2/total protein-protein levels of SERCA2 normalized to total protein levels. The significance of the bold values are represented by p value placed in the table.
alone, and the knockout animals presented only moderate functional LV impairment [19] .
In the present study we showed that both SERCA2a and 2b isoforms (at the mRNA levels) presented significant and parallel down-regulation. Our findings did not reveal any compensational shifts between both isoforms at the mRNA levels.
However, we found the lack of correlation between SERCA2a/2b at the mRNA levels with the LV parameters, confirming the previous findings that mRNA content of SERCA2 is not necessarily transferable to the grade of LV dilatation/dysfunction [20] .
Moreover, the steady state mRNA levels cannot always be assumed to be a certain predictor of protein content and function. The differences in mRNA processing, translation, posttranslational modification, protein synthesis, degradation ratio and function may be attributed to differences in mRNA/protein levels. However, our results confirmed that the decrease in SERCA2 mRNA content parallels a decrease in protein concentration.
The results obtained at the protein levels of SERCA2 in human are more conflicting than at the mRNA levels. The recent results have confirmed that decrease in SERCA2 protein levels in human HF is not an universal finding. Moreover, the changes in SERCA2 protein content can be attributed to the grade of myocardial dysfunction, which was assessed by the force-frequency relation [21] . Also, recently, Hasenfuss et al. [22] reported that discrimination within an heterogeneous group of failing human hearts based on diastolic function lead to two different phenotypes: first with disturbed diastolic function related to unchanged protein levels of the NCX and decreased SERCA2 level and second with preserved diastolic function related to increased protein levels of the NCX and unchanged SERCA2 level. Our results are in concordance with previous findings. Although significantly lower SERCA2 protein levels in MR group to NFH were observed, also the lack of homogeneity within the study group was documented. Moreover, the important negative correlation between SERCA2 protein levels and the LV diastolic size may suggest the association with the preservation diastolic dilatation. Although all correlations have to be interpreted cautiously because in severe MR, due to abnormal loading conditions the assessment of LV function is difficult.
However, more recently works presenting gene transfer techniques, confirmed the importance of reduced SERCA2 protein levels to myocardial dysfunction. Several studies in animal models have reported that SERCA2 gene transfer restored SERCA2 protein expression and activity to nonfailing level which was reflected in restoration of systolic as well as diastolic functions [23, 24] .
In summary, to our knowledge this is the first study showing the decreased mRNA and protein expression of the SERCA2 in LV remodeling due to chronic severe MR. Moreover, correlation of the decreased protein levels which tends to relate to the grade of left ventricular diastolic dilatation suggests that changes in the SERCA2 expression may play an important role in LV volume overload remodeling. We can assume that reduction of SERCA2 protein levels could be attributed to the maladaptation to chronic overload in patients with chronic mitral regurgitation.
Limitations
The results from our study, as from all studies that use tissues obtained from MR and NFH human hearts should be interpreted cautiously. Although the homogeneity in the etiology and standardization of applied treatment in MR group was achieved, the substantial heterogeneity in age, gender, and genes expressions were observed. In addition, non-failing hearts are not necessarily representative of the normal human population. These hearts also did not receive the same treatment as hearts from MR group, moreover, they additionally received low dose of dopamine.
As the LV performance was based on echocardiography that utilized load-dependent parameters, the relation to molecular assessment should be interpreted cautiously. The use of the load-independent methods, e.g., tissue Doppler velocities or pressure/volume loops could enrich LV assessment.
Additionally, between different proteins involved in Ca 2+ movement, we focused only on SERCA2 expression but without differentiation between SERCA2a and 2b on protein level. In spite of all the limitations listed above, we added the new insights into the bases of human LV remodeling secondary to the pure MR in volume overload model, which is still not well defined.
